Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Depreciation and Depletion (2016 - 2024)

Northwest Biotherapeutics (NWBO) has 10 years of Depreciation and Depletion data on record, last reported at $500000.0 in Q2 2024.

  • For Q2 2024, Depreciation and Depletion rose 25.0% year-over-year to $500000.0; the TTM value through Jun 2024 reached $1.7 million, up 21.43%, while the annual FY2024 figure was $1.7 million, 13.33% up from the prior year.
  • Depreciation and Depletion reached $500000.0 in Q2 2024 per NWBO's latest filing, up from $400000.0 in the prior quarter.
  • Across five years, Depreciation and Depletion topped out at $500000.0 in Q2 2022 and bottomed at $2000.0 in Q2 2020.
  • Average Depreciation and Depletion over 4 years is $270500.0, with a median of $350000.0 recorded in 2022.
  • The widest YoY moves for Depreciation and Depletion: up 980.0% in 2020, down 66.67% in 2020.
  • A 4-year view of Depreciation and Depletion shows it stood at $54000.0 in 2020, then soared by 640.74% to $400000.0 in 2022, then changed by 0.0% to $400000.0 in 2023, then grew by 25.0% to $500000.0 in 2024.
  • Per Business Quant database, its latest 3 readings for Depreciation and Depletion were $500000.0 in Q2 2024, $400000.0 in Q1 2024, and $400000.0 in Q4 2023.